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Focal adhesion kinase (FAK) and paxillin are focal
adhesion-associated, phosphotyrosine-containing pro-
teins that physically interact. A previous study has dem-
onstrated that paxillin contains two binding sites for
FAK. We have further characterized these two binding
sites and have demonstrated that the binding affinity of
the carboxyl-terminal domain of FAK is the same for
each of the two binding sites. The presence of both bind-
ing sites increases the affinity for FAK by 5–10-fold. A
conserved paxillin sequence called the LD motif has
been implicated in FAK binding. We show that muta-
tions in the LD motifs in both FAK-binding sites are
required to dramatically impair FAK binding in vitro. A
paxillin mutant containing point mutations in both
FAK-binding sites was characterized. The mutant exhib-
ited reduced levels of phosphotyrosine relative to wild
type paxillin in subconfluent cells growing in culture,
following cell adhesion to fibronectin and in src-trans-
formed fibroblasts. These results suggest that paxillin
must bind FAK for maximal phosphorylation in re-
sponse to cell adhesion and that FAK may function to
direct tyrosine phosphorylation of paxillin in the proc-
ess of transformation by the src oncogene.
Focal adhesion kinase (FAK)1 and paxillin are two focal
adhesion-associated proteins that were initially isolated as
phosphotyrosine containing proteins in src-transformed fibro-
blasts (1, 2). FAK and paxillin colocalize with integrins, which
are transmembrane receptors that engage extracellular matrix
ligands, e.g. fibronectin (3, 4). Upon binding ligand, the inte-
grins trigger cytoplasmic signals that modulate cellular func-
tions (5). One major mechanism of signal transduction utilized
by integrins involves tyrosine phosphorylation of proteins (5,
6). Upon integrin-dependent cell adhesion, FAK becomes tyro-
sine phosphorylated and enzymatically activated. Other focal
adhesion-associated proteins, including paxillin, also become
tyrosine phosphorylated upon cell adhesion. FAK has been
implicated in controlling several integrin-regulated biological
functions including cell spreading, motility, growth, and sur-
vival (7–12).
Several features of FAK that are important for its function
have been defined and include its focal adhesion targeting
(FAT) sequence and its autophosphorylation site. The carboxyl-
terminal domain of FAK contains the FAT sequence and bind-
ing sites for the focal adhesion-associated proteins talin and
paxillin (13–15). FAK autophosphorylates on tyrosine 397, cre-
ating a high affinity Src SH2-binding site (16–18). Src family
kinases associate with FAK using this SH2-binding site and a
proximal Src SH3-binding site in FAK (16, 17, 19–21). Two
proteins that regulate the generation of lipid second messen-
gers, phosphatidylinosotide 39 kinase and phospholipase C-g1,
can also bind to FAK through an SH2-mediated interaction
with tyrosine 397 (22, 23). The association of one or more of
these molecules with FAK is critical for biochemical signaling
and the control of biological responses because mutation of
tyrosine 397 to phenylalanine destroys the signaling capability
and biological activity of FAK (11, 22, 24–26). The recruitment
of Src into complex with FAK may regulate signaling via mul-
tiple mechanisms. First, Src can phosphorylate FAK on a num-
ber of additional tyrosine residues resulting in enhanced cata-
lytic activity and the formation of docking sites for additional
SH2 containing binding partners, e.g. growth factor receptor-
bound protein 2 (Grb2) (27, 28). Second, formation of the
FAKzSrc complex may direct tyrosine phosphorylation of addi-
tional focal adhesion-associated substrates, e.g. paxillin and
p130cas. Phosphorylation of these substrates results in the re-
cruitment of additional SH2 domain containing signaling mol-
ecules, e.g. Crk (24, 29, 30).
Paxillin is the prototypical member of a family of proteins
including hic-5 and leupaxin (31, 32). These proteins contain
four carboxyl-terminal LIM (lin-11, isl-1, and mec-3) domains
(31–34), which are double zinc finger motifs that function to
mediate protein-protein interactions (35, 36). The LIM domains
of paxillin and hic-5 target these proteins to focal adhesions
(37–39). The only known paxillin/hic-5 LIM domain binding
partner is a protein-tyrosine phosphatase, PTP-PEST (40, 41).2
However, this phosphatase is not found in focal adhesions (42,
43).3 The amino-terminal regions of these proteins contain
multiple copies of another interaction motif called the LD do-
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main (37). These motifs have been implicated in mediating
binding to FAK, vinculin, the human and bovine papillomavi-
rus E6 protein, and a GTPase-activating protein for the ARF
GTP-binding protein (37, 44–46). The amino-terminal domain
of paxillin contains four tyrosine residues that are sites of
phosphorylation (24, 47).3 hic-5 and leupaxin may also be phos-
phorylated on tyrosine, although the sites of tyrosine phospho-
rylation in paxillin are not conserved in these proteins (31, 48).
The role of tyrosine phosphorylation and the biological function
of paxillin have not been definitively established. Dominant
negative mutants of FAK have been used to explore FAK func-
tion and have implicated FAK in controlling the rate of cell
spreading in CE cells. In this system, reduced tyrosine phos-
phorylation of paxillin was correlated with the spreading de-
fect, suggesting that paxillin may play a role in this function
(25).
The importance of the physical interaction between FAK and
paxillin has not been firmly established. It is clear that this
interaction is not required for the correct localization of paxillin
to focal adhesions because the FAK-binding site is in the amino
terminus of paxillin and the focal adhesion targeting sequence
is in its carboxyl terminus (37). FAK is proposed to target to
focal adhesions via paxillin binding because a number of FAK
mutants defective for paxillin binding are also defective for
localization to focal adhesions (49). However, there are several
FAK mutants that are unable to bind paxillin yet correctly
target to focal adhesions (13).4 One other potential role for the
FAK-paxillin interaction is to direct tyrosine phosphorylation
of paxillin. In this manuscript, we describe further character-
ization of the two FAK-binding sites within paxillin (37). Both
binding sites interact with the same affinity with FAK and the
FAK-related PTK, CAKb/Pyk2/CadTK/RAFTK. A paxillin mu-
tant with lesions in each of the FAK-binding sites has been
engineered and expressed. Tyrosine phosphorylation of wild
type paxillin and this mutant was examined in cells in culture,
following adhesion to fibronectin and in src-transformed fibro-
blasts. The FAK-binding mutant was tyrosine phosphorylated
under each of these conditions, although the level of phospho-
rylation was reduced relative to wild type. These results sug-
gest that FAK binding is not essential for tyrosine phosphoryl-
ation of paxillin but that association with FAK may enhance
tyrosine phosphorylation of paxillin.
EXPERIMENTAL PROCEDURES
Cells—CE cells were prepared and maintained as described previ-
ously (50). As described previously, paxillin, FAK, and Src were exog-
enously expressed using the replication competent, avian retroviral
vectors RCAS (24, 51). CE cells were transfected or infected with stocks
of retrovirus (for coexpression) as described previously (50). For cell
adhesion experiments, cells were trypsinized and the trypsin was neu-
tralized by washing in soybean trypsin inhibitor. Cells were resus-
pended in serum-free Dulbecco’s modified Eagle’s medium and then
held in suspension or plated onto 100-mm2 Petri dishes coated with
fibronectin (50 mg/ml in phosphate-buffered saline) for 1 h at 37 °C.
After incubation at 37 °C, the cells were lysed.
Molecular Biology—The avian paxillin cDNA was subcloned into the
EcoRI site of pBluescript for subsequent manipulations. An epitope-
tagged derivative of paxillin was engineered using polymerase chain
reaction (PCR) to amplify the paxillin cDNA. One primer (the T7
primer) annealed to the vector, and the second primer altered the
termination codon and created a HindIII site at the 39 end of the coding
sequences. The PCR product was inserted between the EcoRI and
HindIII sites of pBSctag in-frame with the sequences encoding the KT3
epitope tag (51). A PCR-based mutagenesis strategy was utilized to
create point mutations. Complementary primers containing the desired
point mutation(s) were used for amplification of epitope-tagged paxillin
(in pBluescript) using Pfu polymerase (Stratagene, La Jolla, CA). The
product was digested with DpnI and introduced into Escherichia coli
DH5. Successfully mutated clones were identified by nucleotide se-
quencing. The alterations to FAK-binding site 1 (substitution of alanine
for aspartic acid 146) and FAK-binding site 2 (substitution of alanine
for aspartic acid 268) were made sequentially. The epitope-tagged wild
type and mutant paxillin sequences were subcloned into RCAS A.
Fragments of paxillin were expressed as GST fusion proteins. The
fusion proteins were designed based upon the secondary structure
predications of paxillin. The amino terminus of each fragment was
chosen to correspond to the beginning of a predicted a-helix, and the
carboxyl terminus of each fragment was designed to correspond to the
end of a predicted a-helix. Paxillin fragments were amplified by PCR
using primers that created a BamHI site at the 59 end and an EcoRI site
at the 39 end. The fragments were subcloned into pGEX2TK in-frame
with the GST coding sequences. Thus three fusion proteins were engi-
neered, GST-PaxN1-C3 (containing codons 113–312), GST-PaxN2-C3 (con-
taining codons 219–312), and GST-PaxN1-C1A (containing codons 113–
229). Point mutations were engineered in these constructs using the
strategy outlined above. Aspartic acids 146, 268, and 303 were targeted
for mutagenesis and were converted to alanine residues. GST con-
structs harboring these point mutations individually and in combina-
tion were created. GST-FAK fusion proteins have been described pre-
viously (52).
The sequences encoding the carboxyl-terminal domain of FAK were
mutated using the Altered Sites mutagenesis protocol (Promega, Mad-
ison, WI).4 Mutated DNA sequences were amplified by PCR and sub-
cloned into a pBluescript-FRNK plasmid (51) and then subcloned into
RCAS A.4
Nucleotide Sequencing—Two sequencing strategies were utilized.
First, clones that were successfully altered by site-directed mutagenesis
were identified by nucleotide sequencing using a Sequenase kit (Amer-
sham Pharmacia Biotech). Secondly, all amplified sequences were com-
pletely sequenced to verify that no unintended mutations were intro-
duced during the procedure. DNA was sequenced at the UNC-CH
Automated DNA Sequencing Facility on a model 377 DNA Sequencer
(Perkin-Elmer, Applied Biosystems Division) using the ABI PRISMTM
Dye Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq
DNA Polymerase, FS (Perkin-Elmer, Applied Biosystems Division).
GST Fusion Proteins—Overnight cultures were diluted 1:10 and
incubated for 2 h at 37 °C. Expression was induced by the addition of
isopropyl-1-thio-b-D-galactopyranoside (0.1–0.3 mM) and further incu-
bation at 37 °C or room temperature for 4–5 h. Cells were harvested by
centrifugation and stored at 220 °C. For extraction and purification of
protein, the cell pellets were resuspended in NETN buffer containing
protease inhibitors and 2 mM b-mercaptoethanol (53). Aliquots were
sonicated, and cellular debris was removed by centrifugation. The clar-
ified supernatants were incubated with glutathione-agarose beads (Sig-
ma) for 1 h at 4 °C, washed, and finally resuspended in an equal volume
of phosphate-buffered saline. The fusion proteins were analyzed by
SDS-polyacrylamide gel electrophoresis and Coomassie Blue staining.
For some applications the GST fusion proteins were eluted with gluta-
thione buffer (50 mM Tris, pH 8.0, 20 mM glutathione).
The carboxyl-terminal domains of FAK and CAKb were cleaved from
GST and purified as follows. Bacterial lysates were precipitated with
ammonium sulfate at 4 °C for 20 min. The pellet was collected by
centrifugation and resuspended in buffer A (20 mM Tris, pH 7.5, 0.2 M
NaCl, 1 mM b-mercaptoethanol, 5 mM CaCl2). The sample was further
dialyzed against this buffer for 1 h at 4 °C. Approximately 105 mg of
thrombin (Hematologic Technologies Inc., Essex Junction, VT) was
added, and the sample was incubated at room temperature for 30 min.
EDTA was added to a final concentration of 5 mM to stop the reaction.
The sample was clarified by centrifugation, and the FAK/CAKb pro-
teins were purified by chromatography on three columns. The samples
were first run on a DEAE-Sepharose column equilibrated in elution
buffer (20 mM Tris, pH 7.5, 0.2 M NaCl, 1 mM b-mercaptoethanol, 1 mM
EDTA). Then the samples were run on a Sephadex G75 column equil-
ibrated with elution buffer and finally on a hydroxylapatite column
equilibrated with buffer B (20 mM K2HPO4, pH 8.4, 0.2 M NaCl, 1 mM
b-mercaptoethanol). After each column, fractions containing the FAK/
CAKb proteins were identified by monitoring absorption at A280 and
A260 and verified by SDS-polyacrylamide gel electrophoresis and Coo-
massie Blue staining. The fractions were pooled and concentrated using
centricon concentrators (Amicon, Beverly, MA) before loading onto the
next column.
Protein Analysis—Cells were lysed in modified RIPA buffer (50 mM
Tris, pH 7.3, 150 mM NaCl, 1% IPEGAL (equivalent to Nonidet P-40),
0.5% deoxycholate) or Tx-RIPA buffer (50 mM Tris, pH 7.3, 150 mM
NaCl, 1% Triton X-100, 0.5% deoxycholate) containing 50 mg/ml leupep-
4 M. Cooley, J. M. Broome, and M. D. Schaller, manuscript in
preparation.
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tin, 1 mM phenylmethylsulfonyl fluoride, 0.05 trypsin inhibitor units/ml
aprotinin, 2 mM EDTA, and 2 mM vanadate. The protein concentration
of lysates was determined using the bicinchoninic acid assay (Pierce).
Immunoprecipitations were performed using 0.5–1 mg of protein and
approximately 5 mg of purified antibody or 5 ml of antiserum. After
incubation on ice for 1 h, immune complexes were collected using
protein A-Sepharose beads (Sigma) or goat anti-mouse agarose beads
(Sigma) by incubation at 4 °C for 1 h. The immune complexes were
washed twice in lysis buffer and twice in Tris-buffered saline and eluted
in Laemmli sample buffer (54). The samples were analyzed by Western
blotting. FAK antibodies BC4 (equivalent to BC3) and 2A7 and the KT3
monoclonal antibody recognizing the KT3 epitope tag were gifts of Dr.
Tom Parsons. A paxillin monoclonal antibody and the RC20 phospho-
tyrosine antibody were purchased (Transduction Laboratories, Lexing-
ton, KY). A paxillin polyclonal antiserum was prepared as described
below.
Generation of a Paxillin Polyclonal Antiserum—GST-PaxN1-C3 (con-
taining amino acids 113–312 of paxillin) was used as antigen to prepare
polyvalent rabbit antiserum as described previously (55). The fusion
protein was purified on glutathione beads, eluted with 1% SDS, and
extensively dialyzed against phosphate-buffered saline. For primary
immunizations, 1 mg of fusion protein in phosphate-buffered saline was
emulsified with complete Freund’s adjuvant and injected subcutane-
ously into female New Zealand White rabbits. For all boosts, 500 mg of
antigen in phosphate-buffered saline was emulsified with Freund’s
incomplete adjuvant and injected subcutaneously. Serum was prepared
by centrifugation of cellular and clotted material from whole blood. The
antiserum was characterized using immunoprecipitation and Western
blot analyses of lysates of CE cells. Specificity of the antiserum was
determined by comparison with preimmune serum.3
In Vitro Binding Assays—For in vitro binding assays using GST
fusion proteins, cell lysates were precleared with GST immobilized to
glutathione beads (10 mg of GST/mg of lysate) for 1 h at 4 °C. The
cleared supernatants were dispensed into 200-mg aliquots and incu-
bated with 1, 5, or 10 mg of GST fusion protein immobilized on gluta-
thione beads. After incubation at 4 °C for 1 h the beads were collected
by centrifugation and washed twice in lysis buffer and twice in Tris-
buffered saline. The samples were eluted in Laemmli sample buffer (54)
and analyzed by Western blotting.
BIAcore Analysis—Proteins were dialyzed against BIAcore buffer (20
mM Hepes, pH 7.5, 150 mM NaCl, 3 mM EDTA). GST antibody (BIAcore
AB, Uppsala, Sweden) was immobilized on a CM5 sensor chip (BIAcore
AB) with EDC/NHS cross-linking following the manufacturer’s recom-
mended protocol. Two different surface densities (500 and 250 response
units) of GST, GST-PaxN1-C1A, GST-PaxN2-C3, and GST-PaxN1-C3 were
immobilized on the sensor chip by capture with the GST antibody. A
flow cell to which GST alone was captured was also used as a control.
The purified carboxyl-terminal domain of FAK or CAKb was injected
into the flow cell over a range of concentrations (0.039–10 mM), and
BIAcore buffer was used as a blank control. This procedure was then
repeated. Sensorgram signals were corrected by subtracting binding to
the GST control surface. The data were analyzed using the BIAEvalu-
ation version 3.0 software provided with the instrument. This software
performs simultaneous global data fitting of the sensorgrams and pro-
vides reliable estimates of kinetic binding constants. Corrected sensor-
grams were fit to model equations within the BIAEvaluation program
to determine binding affinities. Single site interactions (i.e. between
GST-PaxN1-C1A or GST-PaxN2-C3 and FAK or CAKb) optimally fit to a
1:1 Langmuir (kinetic) model and a steady state affinity (equilibrium)
model, which best described the data. Similar results were obtained
from both methods of analysis. Data fitting was not improved by the use
of more sophisticated binding analysis models. The suitability of the
models for the observed data was determined by chi-square analysis
and residual plot analysis.
RESULTS
Paxillin Contains Two FAK-binding Sites—Previously pub-
lished data demonstrate that two nonoverlapping fragments of
paxillin contain FAK binding activity (37). We initially sought
to verify this result. Because our early efforts to produce re-
combinant GST paxillin fusion proteins resulted in low yields of
unstable protein, the constructs used in this analysis were
redesigned with consideration of the predicted secondary struc-
ture of paxillin. The amino terminus of each paxillin fragment
was chosen to correspond to the amino terminus of a predicted
a-helix, and the carboxyl terminus of each fragment was cho-
sen to correspond to the carboxyl terminus of a predicted a-he-
lix. Using these constructs high yields of relatively stable fu-
sion proteins, called GST-PaxN1-C1A, GST-PaxN2-C3, and GST-
PaxN1-C3, were produced. GST-PaxN1-C1A contains the first
FAK-binding site, GST-PaxN2-C3 contains the second FAK-
binding site, and GST-PaxN1-C3 contains both (Fig. 1). These
three constructs were used in in vitro binding assays to assess
their ability to associate with FAK. The fusion proteins were
immobilized on glutathione beads and incubated with lysates of
CE cells expressing exogenous, wild type FAK. After collecting
and washing the beads, bound FAK was detected by Western
blotting. As predicted, all three fusion proteins exhibited FAK
binding activity (Fig. 2). The GST negative control did not show
any detectable FAK binding activity. In addition, all three of
the GST-paxillin fusion proteins could bind to CAKb/Pyk2/
CadTK/RAFTK in a similar in vitro binding assay.3 To extend
these observations a comparative analysis of the two FAK-
binding sites was performed. Initially, a qualitative estimate of
the relative affinities of each binding site for FAK was deter-
mined by titrating the amount of fusion protein used in the
binding reaction. As the amount of each GST fusion protein
was increased (from 1 to 5 to 10 mg), the amount of bound FAK
was increased (Fig. 2). Binding to GST alone was still unde-
tectable at the highest concentration of fusion protein used.
Approximately equal amounts of FAK bound to GST-PaxN1-C1A
and GST-PaxN2-C3 at each of the concentrations used. As ex-
pected more FAK bound to the GST-PaxN1-C3 fusion protein,
which contained both FAK-binding sites. These results suggest
that the two FAK-binding sites of paxillin have similar affini-
ties for FAK.
To address the affinity of the two binding sites for FAK more
quantitatively, the interaction was examined using BIAcore.
Two different concentrations of GST-paxillin fusion proteins
were immobilized on a BIAcore chip via a GST antibody. The
carboxyl-terminal 134 residues of FAK and carboxyl-terminal
135 residues of CAKb were expressed as GST fusion proteins,
cleaved from GST using thrombin, and purified. A range of
concentrations of these fragments of FAK and CAKb (0.039–10
FIG. 1. Schematic illustration of
paxillin. Paxillin is depicted schemati-
cally. The four carboxyl-terminal LIM do-
mains are indicated. The four white ovals
depict the LD motifs in the amino-termi-
nal half of paxillin. The letter P denotes
the amino-terminal proline-rich region.
Sites of tyrosine phosphorylation (Y) and
aspartic acid residues that are mutated in
this study (D) are also indicated. The pax-
illin sequences included in each of the
GST-paxillin fusion proteins are shown
diagrammatically.
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mM) were injected into the flow cell and data collected. Back-
ground signals, determined using a blank buffer injection and
immobilized GST alone, were subtracted from the data, which
were then analyzed using the BIAEvaluation program. The
sensorgrams generated from these data were fit to model equa-
tions within the program. The single site interactions between
GST-PaxN1-C1A or GST-PaxN2-C3 and the FAK or CAKb frag-
ments equally fit the 1:1 Langmuir kinetic model and a steady
state affinity or equilibrium model. From these analyses, the
binding affinities were determined. GST-PaxN1-C1A and GST-
PaxN2-C3 exhibited very similar dissociation constants for FAK
(Table I). Likewise the two fusion proteins exhibited similar
dissociation constants for CAKb. The dissociation constants for
CAKb were approximately half of the dissociation constants for
the interaction with FAK. The binding affinity of GST-PaxN1-C3
for the carboxyl terminus of FAK was higher than either bind-
ing site alone. The data for the interaction of GST-PaxN1-C3 and
FAK best fit the heterogenous ligand-parallel reactions model
providing two different dissociation constants. The binding af-
finity of GST-PaxN1-C3 for FAK was 5–10-fold higher than the
affinity of either FAK-binding site of paxillin alone. The results
of this analysis demonstrate that the two individual FAK-
binding sites of paxillin exhibit very similar binding affinities
for FAK, and the presence of both binding sites significantly
enhances FAK binding.
LD Domains in Binding Sites 1 and 2 Are Required for FAK
Binding—Mutational analysis of LD domain 2 (which resides
in FAK-binding site 1) has implicated this motif in FAK bind-
ing (37). FAK-binding site 2 contains two LD motifs (LD 3 and
LD 4), and it has been proposed that LD 3 is the critical motif
for FAK binding within this site (37). A mutagenesis approach
was applied to verify the role of LD 2 in FAK binding and to
characterize the second FAK-binding site in paxillin. The as-
partic acid residue in each LD motif was targeted for mutagen-
esis and converted to alanine using a PCR-based mutagenesis
strategy. The mutants were expressed as GST fusion proteins
and assessed for FAK binding in vitro. As described above, a
fusion protein containing binding site 1, GST-PaxN1-C1A, exhib-
ited FAK binding activity (Fig. 3). A comparable fusion pro-
tein containing a single point mutation in LD 2, GST-
PaxN1-C1A/D146A, was completely defective in FAK binding ac-
tivity (Fig. 3). This result verifies that LD2 is critical for the
activity of FAK-binding site 1. A fusion protein containing the
second FAK-binding site, GST-PaxN2-C3, exhibited FAK bind-
ing in vitro. Mutation of LD 4 (GST-PaxN2-C3/D303A) had no
effect upon FAK binding. In contrast, mutation of LD 3 (GST-
PaxN2-C3/D268A) completely abolished the ability of the second
binding site to associate with FAK (Fig. 3). Thus, as proposed,
the LD 3 motif was critical for the association of FAK with
binding site 2. Next, the effect of the LD 2 and LD 3 point
mutations upon the FAK binding activity of a GST fusion
protein containing both FAK-binding sites was assessed. Mu-
tation of either binding site 1 (GST-PaxN1-C3/D146A) or binding
site 2 (GST-PaxN1-C3/D268A) impaired the FAK binding capacity
of these fusion proteins but did not abolish FAK binding (Fig.
3). A double mutant with lesions in both binding sites 1 and 2
(GST-PaxN1-C3/D146A/D268A) very dramatically reduced the abil-
ity of this construct to bind FAK in vitro. These results dem-
FIG. 2. Two FAK-binding sites in paxillin. 200 mg of lysate from
CE cells expressing FAK was precleared with GST and then incubated
with various concentrations of GST-PaxN1-C1A (lanes 3–6), GST-
PaxN2-C3 (lanes 7–10), or GST-PaxN1-C3 (lanes 11–14). 10 mg (lanes 6, 10,
and 14), 5 mg (lanes 5, 9, and 13), 1 mg (lanes 4, 8, and 12), and 0.1 mg
(lanes 3, 7, and 11) of each fusion protein was used. As a control, 10 mg
of GST was used (lane 2). 25 mg of lysate was loaded as a blotting control
(lane 1). Bound FAK was detected by Western blotting. 1 and 5 mg of
each GST fusion protein was analyzed by SDS-polyacrylamide gel elec-
trophoresis and Coomassie Blue staining (bottom panel).
TABLE I
Binding affinities of FAK and CAKb for GST-paxillin fusion proteins
The affinities of FAK and CAKb for different GST-paxillin fusion
proteins was determined by surface plasmon resonance. The dissocia-
tion constant for each interaction (6 standard deviation) is shown.
FAK CAKb
mM
GST-PaxN1-C1A 3.92 6 1.27 1.82 6 0.53
GST-PaxN2-C3 3.63 6 1.55 1.58 6 0.27
GST-PaxN1-C3 0.25 6 0.082 (KD1)
GST-PaxN1-C3 0.69 6 11.9 (KD2)
FIG. 3. Mutation of two LD motifs is required to impair FAK
binding. Lysate from CE cells expressing FAK was precleared
with GST and then incubated with 10 mg of GST (lane 2), GST-
PaxN1-C1A/D146A (lane 3), GST-PaxN1-C1A (lane 4), GST-PaxN2-C3/D268A
(lane 5), GST-PaxN2-C3/D303A (lane 6), GST-PaxN2-C3 (lane 7), GST-
PaxN1-C3/D146A (lane 8), GST-PaxN1-C3/D268A (lane 9), GST-PaxN1-C3/D303A
(lane 10), GST-PaxN1-C3 (lane 11), and GST-PaxN1-C3/D146A/D268A (lane
12) immobilized to glutathione beads. Bound FAK was detected by
Western blotting (top panel). An equal amounts of each GST fusion
protein was analyzed by SDS-polyacrylamide gel electrophoresis and
Coomassie Blue staining.
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onstrate that both LD 2 and LD 3 of paxillin contribute to FAK
binding in vitro and that both binding sites must be disrupted
to dramatically inhibit association with FAK in vitro.
Interaction of FRNK Mutants with GST-Paxillin Fusion Pro-
teins—Because paxillin exhibits two FAK-binding sites, exper-
iments were performed to examine whether FAK contained a
single or multiple paxillin-binding sites. Deletion analysis of
the carboxyl terminus of FAK did not resolve this issue, be-
cause deletions apparently alter the conformation of the car-
boxyl terminus of FAK ablating all of its functions (13). A series
of point mutations has been engineered in the FAT sequence of
FAK.4 Residues that are conserved between FAK and the re-
lated PTK, CAKb, were targeted for mutagenesis. This region
of FAK is predicted to form several amphipathic a-helices.
Mutations were designed to remove large hydrophobic groups
or charged groups from one face of an a-helix by substitution
with alanine resides. A detailed analysis of these mutants will
be presented elsewhere.4 These reagents were utilized to fur-
ther characterize recognition of FAK sequences by each of the
FAK-binding sites in paxillin. For this purpose, the mutants
were engineered into the FRNK cDNA and expressed in CE
cells using the RCAS A vector.4 Expression of each protein was
verified by Western blotting (Fig. 4A). Lysates were incubated
with GST-PaxN1-C1A, GST-PaxN2-C3, and GST-PaxN1-C3, and
bound FRNK was detected by Western blotting with BC4.
GST-PaxN1-C3 associated with exogenously expressed wild type
FRNK (Fig. 4B). FRNKE291/K295 also bound to GST-PaxN1-C3,
although its binding activity was reduced relative to that of
wild type FRNK. Two FRNK mutants, FRNKE255/K262/R269 and
FRNKH332/K339, both exhibited very weak binding to GST-
PaxN1-C3 (Fig. 4B and data not shown). Three other mutants of
FRNK, FRNKV261/L268, FRNKE289/D300, and FRNKL334/L341, did
not detectably associate with GST-PaxN1-C3 because the signal
on the FRNK blot did not exceed the signal produced by endog-
enous wild type FRNK recovered from control lysates. Very
similar results were obtained using GST-PaxN1-C1A (containing
FAK-binding site 1). Thus, GST-PaxN1-C1A associated with wild
type FRNK and FRNKE291/K295 but bound very poorly or not at
all to each of the other FRNK mutants (Fig. 4C). In contrast,
GST-PaxN2-C3 interacted with the FRNK mutants slightly dif-
ferently. GST-PaxN2-C3 bound wild type FRNK but bound very
weakly to FRNKE291/K295 and poorly if at all to the other mu-
tants (Fig. 4D). This analysis has not revealed two distinct
sequences on FAK that are required for interaction with each of
the FAK-binding sites on paxillin, because most of the muta-
tions analyzed equally perturbed binding to each fragment of
paxillin. This result is consistent with the hypothesis that
there is a single site on FAK that can interact with two distinct
binding sites on paxillin. However, there may be particular
residues in FAK that are more important in the interaction
with one binding site on paxillin than the other, e.g. glutamic
acid 291 or lysine 293 and LD motif 3.
Characterization of LD23 in Vivo—To further characterize
the role of the FAK/paxillin interaction in vivo, a paxillin var-
iant containing two point mutations (paxillinD146A/D268A) was
engineered for expression in avian fibroblasts. To distinguish
exogenous paxillin from endogenous wild type paxillin, the
carboxyl terminus of the protein was engineered to contain the
KT3 epitope tag. The construct was subcloned into the RCAS A
replication competent, avian retroviral vector and introduced
into CE cells. Expression was monitored by Western blotting
whole cell lysates using the KT3 antibody. Whereas no KT3
reactive proteins were present in control CE cells, cells trans-
fected with RCAS A containing epitope-tagged wild type pax-
illin or epitope-tagged paxillinD146A/D268A expressed a 68-kDa
protein that reacted with the KT3 antibody (Fig. 5A). To com-
pare the level of expression of exogenous paxillin with endog-
enous paxillin, whole cell lysates were Western blotted using a
polyclonal antiserum recognizing the amino-terminal half of
paxillin. The results of this analysis reveal that the exogenous
paxillin is expressed at levels severalfold higher than the level
of endogenous paxillin (Fig. 5B).
Once expressed, the mutant paxillin protein was tested for
its ability to bind FAK. A GST fusion protein containing FAK
FIG. 4. Association of GST-paxillin fusion proteins with mu-
tants of FRNK. A, lysates of CE cells expressing wild type FRNK (lane
1), FRNKV261/L268 (lane 2), FRNKE298/D300 (lane 3), FRNKE291/K295 (lane
4), FRNKH332/K339 (lane 5), or FRNKL334/L341 (lane 6) were analyzed by
Western blotting with BC4. Each lysate was also incubated with GST-
PaxN1-C3 (B), GST-PaxN1-C1A (C), or GST-PaxN2-C3 (D) immobilized on
glutathione beads. The beads were washed, and bound FRNK was
detected by Western blotting with BC4.
FIG. 5. Expression of epitope-tagged paxillin in CE cells.
Epitope-tagged wild type paxillin and paxillinD146A/D268A were engi-
neered into the RCAS A replication competent, avian retroviral vector
and transfected into CE cells. Nine days post-transfection cells were
lysed, and 25 mg of lysate was analyzed by Western blotting with
monoclonal antibody KT3 (recognizing the epitope tag) (A) or with a
paxillin polyclonal antiserum (B). Lysates from cells transfected with
the empty RCAS A vector (lanes 1), cells expressing wild type paxillin
(lanes 2), and cells expressing paxillinD146A/D268A (lane 3) were analyzed.
The position of molecular mass markers are indicated. The arrowhead
in B indicates a protein that reacts with the paxillin monoclonal anti-
body and is presumably hic-5.
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residues 765–1051 was immobilized on glutathione beads and
incubated with lysates of cells expressing epitope-tagged wild
type or mutant paxillin. Binding of the exogenous, tagged pax-
illin was detected by Western blotting using the KT3 antibody
(Fig. 6). Whereas wild type paxillin was readily detected in
complex with GST-FAK, the mutant was dramatically im-
paired in its ability to associate with FAK in vitro, although
some residual binding activity was evident.
A paxillin mutant with defects in FAK-binding site 1 has
been described and was found to correctly localize to fo-
cal adhesions (37). The subcellular localization of paxil-
linD146A/D268A was examined by immunofluorescence using the
KT3 monoclonal antibody. Both the wild type epitope-tagged
paxillin and the mutant correctly targeted to focal adhesions.3
These results verify that FAK binding is not required for pax-
illin to target to focal adhesions.
Role of FAK Binding in Tyrosine Phosphorylation of Paxil-
lin—Tyrosine phosphorylation of exogenously expressed paxil-
lin was determined by immunoprecipitation with KT3 and
Western blotting. Tagged wild type paxillin was tyrosine phos-
phorylated in a cell adhesion-dependent manner. This protein
contained phosphotyrosine in subconfluent cells growing in
culture, its phosphotyrosine content disappeared when cells
were held in suspension and the protein became tyrosine phos-
phorylated upon cell adhesion to fibronectin (Fig. 7). In sub-
confluent cells growing in culture paxillinD146A/D268A was tyro-
sine phosphorylated, demonstrating that FAK binding was not
essential for tyrosine phosphorylation of paxillin (Fig. 7). How-
ever, the level of tyrosine phosphorylation was reduced relative
to wild type paxillin. This suggests that association with FAK
may be necessary for maximal phosphorylation of paxillin.
Tyrosine phosphorylation of paxillinD146A/D268A was further
characterized. Like wild type paxillin, its phosphotyrosine con-
tent disappeared when cells were held in suspension and tyro-
sine phosphorylation occurred upon cell adhesion (Fig. 7). How-
ever, the level of tyrosine phosphorylation following cell
adhesion was also reduced compared with the level of phospho-
rylation of the wild type protein, suggesting that the interac-
tion of FAK with paxillin was required for optimal tyrosine
phosphorylation following the physiological stimulus of cell
adhesion.
Paxillin was originally identified as phosphotyrosine con-
taining protein in src-transformed fibroblasts. Therefore tyro-
sine phosphorylation of the tagged wild type and mutant pro-
tein was examined following transformation by src. Both the
wild type and mutant protein exhibited elevated levels of tyro-
sine phosphorylation in src-transformed cells (Fig. 8). Again
tyrosine phosphorylation of paxillinD146A/D268A was reduced
relative to wild type paxillin. These results suggest that FAK
binding may also be important for maximal tyrosine phospho-
rylation of paxillin in response to transformation by the src
oncogene.
DISCUSSION
A previous study has demonstrated that paxillin contains 2
nonoverlapping FAK-binding sites in the amino-terminal half
of the molecule and implicated the LD motifs as sites of inter-
action (37). We have extended these observations and shown by
mutational analysis that a single LD motif in each FAK-bind-
ing site is required for association with FAK. Further, each
binding site was characterized and shown to exhibit similar
affinities for FAK using both semi-quantitative (GST pull-
downs) and quantitative (BIAcore) approaches. Finally a pax-
illin mutant with mutations in both FAK-binding sites was
characterized to assess the importance of FAK binding in reg-
ulating tyrosine phosphorylation of paxillin in vivo. The results
suggest that FAK binding is not absolutely essential for tyro-
sine phosphorylation of paxillin but that the interaction may be
important for optimal phosphorylation.
The interactions of FAK-binding site 1 and FAK-binding site
2 on paxillin with FAK has been analyzed qualitatively and
quantitatively. The two binding sites exhibit similar affinity for
the carboxyl-terminal fragment of FAK, and the dissociation
constant is approximately 4 mM for each. When both binding
sites are present FAK binding is stronger, exhibiting a disso-
ciation constant of 250–600 nM. The affinities of interaction
between FAK and some of its other binding partners have been
measured. The SH2 domain of Src binds to a peptide containing
the autophosphorylation site of FAK with a dissociation con-
stant of approximately 30–50 nM, and the SH3 domain of Src
binds to a proline-rich sequence from FAK with a dissociation
constant of 30 mM (20). The Src family SH2 domains exhibit a
range of affinities for peptide ligands from 3.7 nM to 4.2 mM
(56–59). Similarly, a variety of affinities of SH3 domains for
their ligands have been reported, ranging from 1.48 nM to 91
mM (60, 61). Other domains that mediate protein-protein inter-
actions include PDZ (PSD-95 (post-synaptic density protein),
FIG. 6. Association of paxillinD146A/D268A with a GST-FAK fu-
sion protein. A, lysates of CE cells expressing epitope-tagged wild type
paxillin (lane 1) or paxillinD146A/D268A (lane 2) were analyzed by Western
blotting with KT3. B, each lysate was incubated with a GST fusion
protein containing the FAT sequence of FAK that was immobilized on
glutathione beads. The beads were washed, and bound epitope-tagged
paxillin was detected by Western blotting with KT3.
FIG. 7. Tyrosine phosphorylation of paxillinD146A/D268A. Cells
expressing epitope-tagged wild type paxillin (lanes 1–3) or pax-
illinD146A/D268A (lanes 4–6) were analyzed. Subconfluent cells growing
in culture (lanes 1 and 4), cells held in suspension (lanes 2 and 5), or
cells plated onto fibronectin for 1 h (lanes 3 and 6) were lysed. Exoge-
nous paxillin was immunoprecipitated with the KT3 antibody and
analyzed by Western blotting for phosphotyrosine (top panel). The blot
was stripped and reprobed with the KT3 antibody (bottom panel).
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Dlg (disc large tumor suppressor), and ZO1) domains, which
interact with carboxyl-terminal peptide sequences on their li-
gand, and WW domains, which interact with proline-rich se-
quences (62). Some measurements of the binding affinities of
these domains for ligands have been reported. Interactions of
the PDZ domains of the human homologue of the Drosophila
disc large tumor suppressor gene (hDlg) with a carboxyl-termi-
nal peptide from the plasma membrane Ca21 ATPase 4b iso-
form have been measured using surface plasmon resonance
(63). The affinity of a recombinant fragment of hDlg containing
its first two PDZ domains bound with a dissociation constant of
1.6 nM. The third PDZ domain of hDlg also bound to this
peptide but with a dissociation constant of 1.2 mM. The 45-kDa
subunit of the NF-E2 transcription factor binds to the WW
domain of the WWP.1 protein, and the dissociation constant of
this interaction has been estimated at 5.7 nM (64). Thus the
interaction between FAK and a single, LD-containing binding
site on paxillin is approximately the same affinity as a moder-
ate SH3-mediated interaction and weak SH2- or PDZ-mediated
interactions. Although the presence of both FAK-binding sites
increases the affinity of paxillin for FAK, the strength of the
interaction is still far weaker than high affinity SH3-, SH2-,
PDZ-, or WW-mediated protein-protein interactions.
It seems likely that the two FAK-binding sites on paxillin are
similar and interact with FAK via similar mechanisms. First,
the two sites are related in sequence because each contains an
LD motif. Second, mutation of a single aspartic acid residue in
each of these LD motifs abolishes the ability of the site to
interact with FAK in vitro. This result supports the hypothesis
that the LD motifs are responsible for binding to FAK and that
the two FAK-binding sites interact with FAK in a similar
fashion. It should be noted, however, that paxillin contains four
LD motifs and only two of these motifs are implicated in FAK
binding. LD motif 2 has also been implicated in binding vincu-
lin (37). The LD motifs of paxillin also function in binding the
E6 proteins from papillomaviruses. The first LD motif is the
major site of interaction; however, other LD motifs also appear
to exhibit E6 binding activity (45, 46). LD motif 4 has recently
been shown to bind a GTPase-activating protein for the ARF
GTP-binding protein (44). Because individual LD motifs can
discriminate between binding partners, sequences in addition
to the highly conserved consensus residues within each LD
motif must contribute to the specificity of interaction. It is
unknown which residues in these motifs confer specificity of
interaction.
Given that paxillin contains two FAK-binding sites (37),
multiple models for this interaction can be envisioned. First,
FAK could contain two distinct paxillin-binding sites, one that
engages the first FAK-binding site on paxillin and one that
engages the second FAK-binding site. In this regard, it is
interesting that the site of interaction between vinculin and
paxillin has also been localized to the LD 2 motif (37), although,
unlike FAK, vinculin does not interact with a second binding
site on paxillin. Further, there is sequence homology between
the paxillin-binding site in vinculin and the FAT sequence of
FAK. Mutation of some residues in the sequence of FAK that
are homologous to vinculin disrupts paxillin binding (49). We
have identified additional residues outside of the region of
vinculin homology in FAK that are important for paxillin bind-
ing.4 Thus one can imagine that vinculin homologous se-
quences in FAK bind to the first FAK-binding site in paxillin
and a second, unrelated sequence in FAK binds to the second
paxillin interaction site. A second model of interaction between
FAK and paxillin could involve two similar paxillin-binding
sites on FAK, each of which could bind to either FAK-binding
site on paxillin. In the third model of interaction, FAK contains
a single paxillin-binding site that can interact with each FAK-
binding site in paxillin. It has not been possible to directly test
the hypothesis that FAK contains two paxillin-binding sites via
deletion analysis because deletions within the FAT sequence
abolish all of its functions presumably because of perturbation
of structure (13). We have attempted to distinguish between
these models using point mutations in FRNK. Each of these
mutants contain two or three clustered alanine substitutions.
Most of the mutants tested were defective for binding to all
three GST-paxillin fusion proteins. In mutagenesis studies
there is always the concern that the introduced point mu-
tations may perturb structure. This is unlikely to be the case
for these mutants because all of the mutants, except for
FRNKL334/L341, can effectively target to focal adhesions.4 Thus,
the engineered mutations do not globally perturb the structure/
function of the FAT sequence but specifically reduce paxillin-
binding activity. The evidence presented in this paper does not
strongly support the first model of interaction that postulates
two distinct paxillin-binding sites on FAK. FRNKL334/L341 con-
tains one point mutation in the region of vinculin homology.
FRNKV261/L268 and FRNKE289/D300 contain point mutations
outside of the region of vinculin homology. Each of these mu-
tants is defective for interaction with both the first and second
binding sites of FAK. Because most of the FRNK mutants are
equally defective at binding to GST fusion proteins containing
the first FAK-binding site of paxillin, the second FAK-binding
site of paxillin or both binding sites, there do not appear to be
two distinct paxillin-binding sites in FAK. The single exception
is FRNKE291/K295, which can bind GST-PaxN1-C1A but binds
very weakly to GST-PaxN2-C3. However, we have not identified
mutations that perturb binding to GST-PaxN1-C1A and retain
the ability to bind GST-PaxN2-C3. This analysis and a second
FIG. 8. Tyrosine phosphorylation (ptyr) of paxillinD146A/D268A in
src-transformed cells. CE cells expressing epitope-tagged wild type
paxillin (lane 1) or paxillinD146A/D268A (lane 2) were superinfected with
an avian retrovirus containing an oncogenically active variant of Src.
Upon transformation of the cells, the wild type and mutant proteins
were immunoprecipitated from cell lysates using KT3. The proteins
were analyzed by Western blotting for phosphotyrosine (top panel). The
blot was stripped and reprobed with KT3 (bottom panel).
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published report describing point mutations in the FAT se-
quence of FAK do not support the model that there are two
related paxillin-binding sites in FAK (49). If this scenario oc-
curred, one would predict that multiple mutations in different
regions of the FAT sequence would be required to perturb
paxillin binding. In contrast to this prediction, individual point
mutations or clusters of point mutations are sufficient to dis-
rupt paxillin binding (49).4 Because our data do not support the
alternative models, the current favored hypothesis is that FAK
contains a single paxillin-binding site that can interact with
both FAK-binding sites on paxillin. However, the paxillin-bind-
ing site of FAK interacts slightly differently with the two FAK-
binding sites of paxillin because mutation of glutamic acid 291
and lysine 295 of FRNK perturb binding to one site and not the
other.
Regardless of the precise mechanism by which FAK and
paxillin interact, it is intriguing that paxillin contains two
FAK-binding sites. Clearly one of the functions is to increase
the affinity of interaction as demonstrated in the BIAcore ex-
periments. The presence of two lower affinity binding sites that
function together to produce high affinity binding raises an
interesting hypothesis regarding regulation of the interaction.
The overall affinity of the interaction between FAK and paxil-
lin might be regulated by controlling the binding activity of
each of the FAK-binding sites on paxillin.
Using a paxillin mutant defective for FAK binding, we have
explored the role of FAK association in regulating tyrosine
phosphorylation of paxillin. The mutant does contain phospho-
tyrosine, although the level of phosphorylation is decreased,
clearly implicating FAK association as a prerequisite for max-
imal tyrosine phosphorylation. Although paxillinD146A/D268A is
defective for FAK binding, it still exhibits some residual bind-
ing activity. Perhaps FAK binding is absolutely required for
tyrosine phosphorylation of paxillin and the residual binding
activity of paxillinD146A/D268A is sufficient to cause the level of
tyrosine phosphorylation observed. A more likely scenario is
that there are alternative mechanisms by which paxillin can
become tyrosine phosphorylated. Mutants of FAK that fail to
associate with paxillin can induce its tyrosine phosphorylation,
suggesting that some degree of FAK-dependent tyrosine phos-
phorylation can occur independent of physical association (65).4
Perhaps colocalization of FAK with paxillin is sufficient to
induce some paxillin phosphorylation, although the possibility
that the association of endogenous FAK with paxillin is re-
quired for phosphorylation of paxillin under these conditions
cannot be excluded. There are also three other PTKs that could
function in the tyrosine phosphorylation of paxillin. Src family
kinases have been implicated in tyrosine phosphorylation of
paxillin (24, 66), and paxillin contains a proline-rich sequence
that can serve as a docking site for the SH3 domain of Src (67).
Carboxyl-terminal Src kinase (Csk) has also been reported to
associate with paxillin and induce its tyrosine phosphorylation
(68, 69). Paxillin may also be a substrate for Abl because
tyrosine phosphorylation of paxillin is induced upon transfor-
mation with the Abl oncogene (34, 70). In addition, Abl was
found to transiently associate with paxillin following cell adhe-
sion and to phosphorylate paxillin in vitro (71). Thus there are
multiple mechanisms by which paxillin could be tyrosine phos-
phorylated in the absence of its interaction with FAK.
It is apparent that association with FAK is required for
maximal phosphorylation by FAK. Thus this interaction could
target paxillin for direct phosphorylation by FAK. Alterna-
tively, because FAK binds Src family PTKs, association with
FAK may be a mechanism to recruit paxillin for phosphoryla-
tion by these PTKs. It is interesting to observe that
paxillinD146A/D268A shows reduced tyrosine phosphorylation in
src-transformed cells. This observation implicates FAK directly
or indirectly in targeting paxillin for phosphorylation during
transformation and suggests a possible role for FAK in trans-
formation by the Src oncogene. There are two possible expla-
nations for the observed reduction in phosphorylation of
paxillinD146A/D268A. First, the interaction with FAK allows pax-
illin to be phosphorylated more efficiently. The second and
more interesting hypothesis is that the interaction with FAK
directs tyrosine phosphorylation of specific residues on paxillin.
This would have important implications for regulating the as-
sociation of signaling molecules with paxillin and the subse-
quent generation of downstream signals.
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